Mangoceuticals, Inc. (MGRX): Cash & Equivalents

Annual figures by period end, from SEC filings.

$1.49M
As of 2025-12-31
$228.7K
As of 2026-06-30
+29.6%
3-year compound annual growth
2022-12-31: $682.9K2023-12-31: $739.0K2024-12-31: $58.7K2025-12-31: $1.49M$1.49M
2022-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$1.49Mn/m2026-04-01, Balance as of period end
2024-12-31$58.7K-92.1%2026-04-01, Balance as of period end
2023-12-31$739.0K+8.2%2025-03-20, Balance as of period end
2022-12-31$682.9Kn/a2024-04-01, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Services-Misc Health & Allied Services, NEC), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
Mangoceuticals, Inc. (MGRX)2025-12-31$1.49Mn/m
BioRestorative Therapies, Inc. (BRTX)2025-12-31$1.51M+175.8%
Charming Medical Ltd (MCTA)2026-03-31$4.70M+475.3%
Pacific Health Care Organization Inc (PFHO)2025-12-31$2.17M+4.7%
Marpai, Inc. (MRAI)2025-12-31$133.0K-82.6%
Cryo Cell International Inc (CCEL)2025-11-30$319.0K-43.1%
Viemed Healthcare, Inc. (VMD)2025-12-31$13.50M-23.0%
Sotera Health Co (SHC)2025-12-31$344.62M+24.3%
Progyny, Inc. (PGNY)2025-12-31$112.24M-30.9%

Compare MGRX, BRTX, MCTA, PFHO side by side · Screen every company in Services-Misc Health & Allied Services, NEC ↗